HIF1A and age-related macular degeneration: Another notable innovation includes the use of anthracycline antibiotics in targeted, sustained-release drug delivery systems such as nanoparticles, microspheres, and hydrogels to inhibit HIF-1 activity, effectively treating AMD symptoms with effects lasting up to two months per administration (CN103083341A) [108].